Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive:

JHOP Print Edition

JHOP Weekly e‑Newsletter

I have reviewed and consent to the terms of JHOP's Privacy Policy, and JHOP has my permission to retain my information in its database, and to forward pertinent communications to me.

JHOP - March 2023 Vol 13 Special Feature

Print Hopa Abstracts Download Hopa Abstracts

Clinical Pharmacist–Initiated Tyrosine Kinase Inhibitor Discontinuation in Patients with Chronic Myeloid Leukemia

Evaluation of Chemotherapy-Induced Myelosuppression in Patients with Extensive-Stage Small-Cell Lung Cancer Who Received Trilaciclib: Retrospective Analysis of Florida Community Oncology Practices

Evaluation of the Safety of the New Alcohol-Containing Formulation of Cyclophosphamide

Health System Specialty Pharmacy Integration Impact on Prescription Fill Time

Invasive Fungal Disease in Patients with Hematologic Malignancies Receiving Micafungin Prophylaxis

Knowledge Gaps and Educational Needs for Common Cancer Therapy–Related Cardiovascular Adverse Events and Related Drug Interactions

Featured Articles

Original Article

Comparing the Efficacy and Safety of Reference Drug Filgrastim and Biosimilar Filgrastim-sndz in Pediatric Patients Used for Post–Hematopoietic Stem-Cell Transplant Engraftment or Chemotherapy-Induced Febrile Neutropenia Prophylaxis

Original Article

Dosing of 3 Targeted Agents in Novel Drug Combinations Used at the Precision Medicine Clinic of the University of California San Diego

Original Article

Economic Burden of Cardiovascular Events in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma in the First Year After Initiating Treatment with a Novel Agent

Practical Issues in Pharmacy Management

Cost-Savings Using Patients’ Own Medication Supply of Letermovir for Allogeneic Hematopoietic Stem-Cell Transplant Recipients During Hospitalization

Case Reports

A Pregnant 19-Year-Old Patient with Refractory Immune Thrombocytopenia and Concomitant SARS-CoV-2 Infection: Case Report

Case Reports

Anakinra Used in a Patient with Diffuse Large B-Cell Lymphoma and Steroid-Refractory Immune Effector Cell–Associated Neurotoxicity Syndrome: Case Report

Perspective

“You Have Cancer”

Editorial

Keeping the HOP(A) Live—Annual Conference Research Highlights

FDA Oncology Update

Orserdu FDA Approved for ER-Positive Advanced or Metastatic Breast Cancer with ESR1 Mutation

Jaypirca, a New BTK Inhibitor, Received FDA Accelerated Approval for Relapsed or Refractory Mantle-Cell Lymphoma

FDA Approved Lunsumio for Relapsed or Refractory Follicular Lymphoma

Adstiladrin, First Adenoviral Vector–Based Gene Therapy, FDA Approved for High-Risk Non–Muscle Invasive Bladder Cancer

Krazati Received Accelerated FDA Approval for NSCLC with KRAS G12C Mutation

Keytruda Received FDA Approval for Adjuvant Treatment of Non–Small-Cell Lung Cancer

Tukysa, in Combination with Trastuzumab, Now FDA Approved for HER2-Positive Unresectable or Metastatic Colorectal Cancer

Brukinsa Now FDA Approved for Patients with CLL or SLL

Tecentriq Now FDA Approved for Treatment of Alveolar Soft-Part Sarcoma

Most Popular Articles

JHOP - December 2022 Vol 12, No 6 - Review Article

Pancreatic Cancer: Review of the Current and Investigational Drug Landscape

JHOP - December 2022 Vol 12, No 6 - Original Article

Assessment of the Elimination of Test Doses for Paclitaxel and Carboplatin in Patients with Cancer

JHOP - December 2022 Vol 12, No 6 - Original Article

Incidence of Hypothyroidism in Patients with Cancer Receiving Immune Checkpoint Inhibitors

JHOP - December 2022 Vol 12, No 6 - Case Reports

Neoadjuvant FOLFIRINOX Therapy for a Patient with Borderline Resectable Pancreatic Ductal Adenocarcinoma Undergoing Hemodialysis: Case Report

JHOP - October 2022 Vol 12, No 5 - Original Article

Impact of Pharmacist Telephone Follow-Up on Chemotherapy-Induced Nausea and Vomiting

JHOP - December 2022 Vol 12, No 6 - Original Article

Outcomes and Adverse Events Linked to Off-Label Treatment of Solid Tumors with PARP Inhibitors